GALE 301

Drug Profile

GALE 301

Alternative Names: E39+GM-CSF vaccine; FBP vaccine; Folate Binding Protein-E39 and J65 vaccine; Folate Binding Protein-E39 vaccine; GALE-301

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; University of Texas M. D. Anderson Cancer Center
  • Developer Galena Biopharma; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Peptide vaccines; Peptides; Protein-vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Endometrial cancer; Ovarian cancer
  • Phase I/II Breast cancer

Most Recent Events

  • 17 Mar 2017 Final adverse events data from a phase I/IIa trial in Ovarian and Endometrial cancer released by Galena Biopharma
  • 14 Nov 2016 Analysis of post-booster immunogenicity data from a phase Ib trial in Ovarian cancer and Breast cancer released by Galena Biopharma
  • 20 Oct 2016 Immunogenicity data from a phase Ib trial in Breast cancer and Ovarian cancer released by Galena Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top